Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenza Magagnoli

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Kidney360|April 24, 2025
Calciprotein Particles in CKD: When Good Molecules Go BadLorenza Magagnoli, Mario Cozzolino
Kidney International|February 21, 2026
The authors replyLorenza Magagnoli, Nicholas C Chesnaye
Toxins|June 25, 2025
From Physicochemical Classification to Multidimensional Insights: A Comprehensive Review of Uremic Toxin ResearchMario Cozzolino, Lorenza Magagnoli, Paola Ciceri
Expert Opinion on Investigational Drugs|June 17, 2024
Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugsLorenza Magagnoli, Paola Ciceri, Mario Cozzolino
Journal of Nephrology|February 3, 2021
COVID-19 in a dialysis center in Milan from March to June 2020: understanding how to respond to the second wave of the pandemicAndrea Galassi, Lorenza Magagnoli, Mario Cozzolino, et al.
Clinical Kidney Journal|October 2, 2023
The open system of FGF-23 at the crossroad between additional P-lowering therapy, anemia and inflammation: how to deal with the intact and the C-terminal assays?Lorenza Magagnoli, Mario Cozzolino, Andrea Galassi
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 11, 2022
Beyond vessels and bones: can CKD-MBD treatment improve uraemic subjects' minds?Lorenza Magagnoli, Andrea Galassi, Mario Cozzolino
Expert Opinion on Therapeutic Targets|December 20, 2025
Critical evaluation of therapeutic targeting in chronic kidney disease: where do we stand 5 years on?Mario Cozzolino, Lorenza Magagnoli, Paola Ciceri
Expert Opinion on Pharmacotherapy|June 10, 2026
How are developments in the treatment armamentarium of hyperphosphatemia addressing the current therapeutic challenges?Lorenza Magagnoli, Paola Ciceri, Mario Cozzolino
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|November 6, 2024
[Hypoxia-Inducible Factor Prolyl Hydroxylase Enzyme Inhibitors: A Novel Therapy for Anemia Treatment in CKD Patients]Andrea Stucchi, Lorenza Magagnoli, Anila Cara, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Kidney360|April 24, 2025
Calciprotein Particles in CKD: When Good Molecules Go BadLorenza Magagnoli, Mario Cozzolino
Kidney International|February 21, 2026
The authors replyLorenza Magagnoli, Nicholas C Chesnaye
Toxins|June 25, 2025
From Physicochemical Classification to Multidimensional Insights: A Comprehensive Review of Uremic Toxin ResearchMario Cozzolino, Lorenza Magagnoli, Paola Ciceri
Expert Opinion on Investigational Drugs|June 17, 2024
Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugsLorenza Magagnoli, Paola Ciceri, Mario Cozzolino
Journal of Nephrology|February 3, 2021
COVID-19 in a dialysis center in Milan from March to June 2020: understanding how to respond to the second wave of the pandemicAndrea Galassi, Lorenza Magagnoli, Mario Cozzolino, et al.
Clinical Kidney Journal|October 2, 2023
The open system of FGF-23 at the crossroad between additional P-lowering therapy, anemia and inflammation: how to deal with the intact and the C-terminal assays?Lorenza Magagnoli, Mario Cozzolino, Andrea Galassi
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 11, 2022
Beyond vessels and bones: can CKD-MBD treatment improve uraemic subjects' minds?Lorenza Magagnoli, Andrea Galassi, Mario Cozzolino
Expert Opinion on Therapeutic Targets|December 20, 2025
Critical evaluation of therapeutic targeting in chronic kidney disease: where do we stand 5 years on?Mario Cozzolino, Lorenza Magagnoli, Paola Ciceri
Expert Opinion on Pharmacotherapy|June 10, 2026
How are developments in the treatment armamentarium of hyperphosphatemia addressing the current therapeutic challenges?Lorenza Magagnoli, Paola Ciceri, Mario Cozzolino
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|November 6, 2024
[Hypoxia-Inducible Factor Prolyl Hydroxylase Enzyme Inhibitors: A Novel Therapy for Anemia Treatment in CKD Patients]Andrea Stucchi, Lorenza Magagnoli, Anila Cara, et al.
Pageof 4